PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome
Indian Journal of Cancer · 2025
DOI: 10.4103/ijc.ijc_151_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Cancer, 2025. Verfasst von Khalid Abdul Mannan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
The Immune checkpoint inhibitors (ICI) targeting PDL-1 show improved outcomes in lung adenocarcinoma patients. This study is intended to understand the association of PDL-1 with molecular alterations in non small cell lung cancer patients.
Aims
To correlate clinicopathological features with molecular phenotype across PDL-1 subgroups and analyze survival outcomes for patients having PDL-1 expression (>1%). Materials and Methods: We did a retrospective study of 100 NSCLC cases diagnosed at primary and metastatic sites using a next-generation sequencing (NGS) lung panel and the PDL-1 SP263 clone on the Ventana platform. PDL-1 expression, sample size, sex, histological type, and oncogenic mutation status were analyzed. Patients with PDL-1 expression >1% and managed with immunotherapy (IO), targeted therapy (TT), and conventional chemotherapy (CC) were followed up for a median time of 7 months. The outcome was assessed as overall survival (OS).
Results
Fifty-one percent of the cases showed a positive PDL-1 expression. Squamous cell carcinoma (SCC) exhibited higher PDL-1 expression than adenocarcinoma (AC) ( P -value = 0.005). The KRAS expression was more frequent in males ( P -value = 0.048). There was no difference between the tumor location and the type of sample used. The EGFR mutation was exclusively seen in AC compared with other NSCLCs. The median overall survival in the IO and TT groups was 13 and 11 months, respectively, compared to 7 months in the CC group.
Conclusions
Integrating clinical, molecular, and immunological data will enhance the predictive value of PDL-1 biomarkers in lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India.
- Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India.
ORCID-Profile: Sahithi S Arya
Zitieren
APA
Mannan, K. A., Fonseca, D., Arya, S. S., Vaishnavi, K., Kodandapani, S., & Rajappa, S. J. (2025). PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_151_23
Vancouver
Mannan KA, Fonseca D, Arya SS, Vaishnavi K, Kodandapani S, Rajappa SJ. PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome. Indian Journal of Cancer. 2025. doi:10.4103/ijc.ijc_151_23
BibTeX
@article{Mannan2025,
author = {Mannan, Khalid Abdul and Fonseca, Daphne and Arya, Sahithi S and Vaishnavi, Kunteepuram and Kodandapani, Suseela and Rajappa, Senthil J},
title = {PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome},
journal = {Indian Journal of Cancer},
year = {2025},
doi = {10.4103/ijc.ijc_151_23}
}
EUVIMED